**Title:** Concordance between EMA Good Clinical Practice inspections and medical literature concerning drugs that have not received marketing authorization in the European Union: a meta-research survey

**Authors:** Alexandre Terré[1,2], Ondine Becker[3], John P.A. Ioannidis[4], Florian Naudet[5,6]

**Affiliations:**

1 Department of Internal Medicine, Ambroise Paré Hospital, Boulogne-Billancourt, France

2 Sorbonne Université, Faculté de Médecine

3 Medical Oncology Department, European Hospital Georges Pompidou, Paris, France

4 Departments of Medicine, of Epidemiology and Population Health, and of Biomedical Data Science, and Meta-Research Innovation Center at Stanford (METRICS), Stanford University, CA 94305, USA

5 University of Rennes, CHU Rennes, INSERM, IRSET (Institut de Recherche en Santé, Environnement et Travail)-UMR_S 1085, CIC 1414 (Centre of Clinical Investigation of Rennes), Rennes, France.

6 Institut Universitaire de France (IUF), Paris, France.

ORCID:

Alexandre Terré: 0000-0002-8295-9068

Florian Naudet: 0000-0003-3760-3801

John Ioannidis: 0000-0003-3118-6859

Conflict of interest:

AT received research grants from Institut Imagine, the Societé Nationale Française de Médecine interne and the Fondation Française pour la Recherche contre le Myélome et les Gammapathies monoclonales.

FN received research funding from the French National Research Agency, the French Ministries of Health and Research. FN is a work package leader in the OSIRIS project (Open Science to Increase Reproducibility in Science); the OSIRIS project has received funding from the EU's Horizon Europe research an innovation programme under grant agreement No. 101094725. FN is also a WP leader in the doctoral network MSCA-DN SHARE-CTD (HORIZON-MSCA-2022-DN-01 101120360), funded by the EU.

Funding: FN works on integrity is funded by the French National Research Agency (Research Integrity in Biomedical Research (RestoRes).

Corresponding author:

Dr Alexandre Terré

Address: Ambroise Paré Hospital, Internal medicine department, 9 Avenue Charles de Gaulle, 92100 Boulogne-Billancourt, France.

E-Mail: alexandre.terre@aphp.fr

Keywords: EMA, EPAR, Meta analyses, Post publication peer Review, Good Clinical Practice inspections

Word count: 4798

**Abstract:**

**Objectives** - To describe the differences between European Medicine Agency (EMA) Good Clinical Practice (GCP) inspection reports and medical literature on drugs with withdrawn or refused applications.

**Design** - A retrospective study comparing studies included in European Public Assessment Reports (EPARs) and the corresponding articles published in the medical literature.

**Data sources -** We screened all EPARs released by the EMA from inception to April 2024 for drugs that were refused or had a withdrawn application. In those EPARs, we looked for mentions of GCP inspections and details about them, then we searched for related publications on the inspected studies on bibliographic databases.

**Eligibility criteria -** All EPARs mentioning good clinical practice inspection were included in this survey.

**Data extracted** – Two reviewers independently gathered information on the GCP inspections and their findings, including the EMA's opinion on their impact on the study data. The reviewers checked related publications for mentions of the inspection and any subsequent correction, retraction, or expressions of concern related to its findings.

**Main outcome measures -** The main outcome was the mention of the GCP inspection findings in the publication of the inspected studies. We also assessed whether there was any mention of these findings in a correction, retraction, or expression of concern.

**Results –** Out of 285 EPARs screened, 57 (20%) mentioned a GCP inspection. 58 distinct studies with inspections had 61 publications. For 17 publications the inspection occurred after the publication, for 20 the inspection happened before the publication, and for 24 the date of the inspection was unknown. Only 1 publication (2%) addressed the inspection findings. Moreover, there were no corrections, retractions, or expressions of concern related to inspection findings. Among the 61 publications, 26 (43%) were related with 24 distinct studies that had an inspection that casted doubts on data reliability, but none mentioned the inspections at or after the time of publication.

**Conclusions** – This meta-research survey indicates that health authorities' GCP inspections are not reflected in the published literature, even when the inspections have put the data reliability in doubt. Journals should clearly specify which aspects of those studies are trustworthy and which ones are not.

**Trial registration -** osf.io/pa9fq/

## Introduction

Clinical trials are essential sources of information for healthcare professionals and public health policymakers. Due to the significant impact that their publication in medical literature can have on patient care, it is crucial that this information is trustworthy. Peer review prior to publication serves to identify and rectify errors, thereby ensuring the reliability of the literature. However, peer review has its limitations (1,2). It often faces limited resources, and external experts may struggle to comprehensively address all potential issues within the constrained time frame of reviewing a trial that may span several years. Sometimes criticisms or comments may escape this step, leading to the publication of clinical trials with errors (3–5). In these instances, the literature is expected to self-correct.

Health authorities such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) possess information that may assist in identifying and correcting errors in clinical trials before and/or after publication. They occasionally conduct Good Clinical Practice (GCP) inspections at clinical study sites, providing an in-depth evaluation of crucial steps of clinical trials, such as conduct, data collection, and analysis. The detail provided by such investigations provides material that exceeds what medical journals can offer with peer-review. The report of these inspections, when identifying deficiencies, is crucial and should be known by the end-users. However, it seems that these inspection reports are disconnected from the evidence published in the medical literature. In 2015, Seife identified 57 clinical trials resulting in 78 publications where a GCP inspection by the FDA found deviations from GCP recommendations that could cast doubt on the quality of the information presented in the corresponding publications (6). Yet, in 2015, at the time of Seife's publication, 96% of the articles he identified did not mention these inspections either themselves or through an expression of concern or erratum (6).

This question has not been examined through clinical trials assessed by the EMA. Unlike the FDA, the EMA does not directly publish GCP inspection reports. However, these are referenced in the European Public Assessment Reports (EPAR) issued by the Committee for Medicinal Products for Human Use (CHMP), especially when the outcome of a GCP inspection influences the CHMP's decision to approve or deny a marketing authorization (7). The objective of our study was to determine if the EPARs for drugs submitted to the EMA contain information from GCP inspections that contradicts the medical literature data. To increase the chances of identifying GCP inspections that raised concerns, we focused on marketing applications that were either refused or withdrawn.

## Methods

The methods of this descriptive study were specified in advance in a protocol registered on the Open Science Framework on 31st July 2024 (https://osf.io/pa9fq/). This report provides details and reasons for any deviations from the initial plan. As no reporting guideline exists for such a meta-research survey, we relied on PRISMA (8) which we considered as the most appropriate reporting guideline.

***Eligibility criteria and information sources***

We included EPARs published from the 17th of July 2000 (date of publication of the first EPAR) up to the 1st of April 2024, concerning drugs refused or for which the marketing application has been withdrawn. Among those EPARs, any study with a GCP inspection was included. The EPARs are labelled under the commercial name of the drug on the EMA website, thus here we use this name in our article and for EPARs citations.

***Search strategy***

The assessments of the CHMP are publicly available on the EMA website, under the name of European public assessment reports (EPAR) (9). Using the search function on the EMA website, we searched the published assessments reports using the filters "human," "Medicines," "Withdrawn application," "refused."

For each identified assessment, we searched the available documents on the EMA website for mentions of a GCP inspection conducted by the EMA by searching the terms "Good clinical practice" or "GCP" used in these reports. We preferably used the document "EPAR - Public assessment report." We also searched, when available, in the paragraph: "Steps taken for the assessment of the product." In the absence of this document, the other documents presented on the EMA website ("withdrawal letter", or "Question-Answer") were also screened.

***Selection and data collection processes***

Screening of EPARs and data collection of verbatim quotes were done independently by two authors (AT and OB). Contrary to our initial protocol, discrepancies were first resolved through consensus before being arbitrated by a third author (FN).

***Data items***

*Assessment report data*

For each identified EPAR, we recorded the opinion date, the commercial name of the drug, the international non-proprietary name, whether the application was refused or withdrawn, and whether a GCP inspection conducted by the EMA was mentioned.

When a GCP inspection was identified, we extracted whether it was described and if deviations were mentioned in the EPAR. For each study subject to a GCP we noted if the results of the inspection impacted the efficacy criterion, the safety/tolerance profile of the drug, or an

ethical rule. The deviations observed by the EMA are classified as "critical," "major," or "minor". Critical findings are defined as “conditions, practices, or processes that adversely affect the rights, safety or wellbeing of the subjects and/or the quality and integrity of data”. Major findings are defined as “conditions practices or processes that might adversely affect the rights, safety or wellbeing of the subjects and/or the quality and integrity of data. Major observation are serious deficiencies and are direct violation of GCP principles”. Minor deviations are defined as “conditions, practices or processes that would not be expected to adversely affect the right, safety or wellbeing of the subjects and/or the quality and integrity of data” (10).

We extracted information following this classification by using the exact terms employed in the report. As the EPARs sometimes describes the number of deviations observed by category, we extracted the number of “critical” deviations per GCP inspection. If the EPAR detailed the verbatim elements of the GCP inspection influencing its decision, these elements were collected in free text. Finally, we looked at the conclusions issued by the CHMP concerning the impact of deviations eventually observed on the results presented. To clarify this last aspect, we had to refine data analysis process during our study because the classification of the findings as “critical”, “major” or “minor” was frequently missing or was not related to the reliability of the data as assess by the CHMP. Using the verbatim text presented in the EPAR we extracted the opinion of the EMA on the effect of the GCP findings on the reliability of the data. The findings were classified as “impacting the reliability of the data”, or “not impacting the reliability of the data”. If the opinion was not described, or ambiguous, the opinion was classified as “unknown”. We also examined whether the GCP inspection referenced any deviations from ethical guidelines.

*Subsequent publications*

For each mention of a GCP inspection, we searched if one or more of the corresponding studies were published in a peer-reviewed medical journal. The EPARs were searched under "Clinical efficacy" and "Main studies" for any EU Clinical Trials Register or ClinicalTrials.gov trial identification number or study number used by the sponsor. If only a sponsor's study number was available, we searched in Google for its match with a Clinical trial number, using the sponsor’s study number and international non-proprietary name of the drug. Then, we searched in Google Scholar and study registries for the clinical studies published in medical journals using the identification number. We considered both studies published as articles and as abstracts or conference presentations and recorded separately the results published in articles and those posted in abstracts or conference presentations. In the absence of an identification

number, we searched in free text the descriptive elements of the study using the drug's name (commercial or international non-proprietary name), study design regarding randomization, comparator, the presence of blinding (single or double), and the medical indication (disease name with stage if specified) in the Google search engine. We used the number of patients and the inclusion dates to confirm that the studies found correspond to those mentioned in the EPAR. We collected all retrieved publications even when there were multiple publications for a given trial. For each identified publication, we examined references to the GCP inspection and its conclusions. We also searched for corrections, retractions or expression of concerns mentioning the GCP findings on Pubmed and on the journal website. This outcome was added during the research because many articles were published before the EPAR, so the initial version of the article was not expected to mention the GCP inspection. During the study, a search was added on the Pubpeer website (11) for any comments posted about the articles.

*Dissemination in meta-analyses, reviews, and citation count*

For each identified publication, we used the Web of Science search engine to collect the citation count of each study and specifically study the number of meta-analyses citing them. This was done between the 2nd of January and the 5th of February 2025.

*Detailed inspection reports*

To obtain comprehensive details of each GCP inspection revealing critical or major deviations and resulting in a scientific publication, we requested the complete GCP inspection report from the EMA. This request was made in accordance with Article 7 of Regulation (EC) No 1049/2001 regarding public access to European Parliament, Council, and Commission documents (the Regulation) and Section 3 of the Annex to the "European Medicines Agency policy on access to documents - POLICY/0043"(12). According to this policy, all documents from EU Institutions and European decentralized Bodies such as the European Agencies are accessible to the public. For each request we noted the date on which the request was made. We noted how long it took the EMA to respond to our request, and the answer we received. We planned that if there was no response after one year, we would consider the EMA did not address our request.

***Outcomes***

The primary outcome was the mention of the deviation and/or of the EMA GCP inspection in the publication. This definition had to be enhanced by incorporating information on corrections, retractions, or expressions of concern related to the GCP findings. The secondary outcomes were 1/ description of the deviations in the EPAR, both qualitatively and quantitatively, 2/ discordance between the deviations described in the EPAR and the publication, 3/ description

of publications in terms of journal and date, 4/ dissemination of the studies with data reliability issues identified by the EMA in journals and meta-analyses and 5/ comments on Pubpeer about the GCP inspection (this outcome was added during the study).

***Analysis***

We described quantitative variables using means (± standard deviations, SD) or medians (interquatrile range, IQR), as appropriate. We described qualitative variables using numbers and percentages. Verbatim text is presented to describe findings of the GCP inspections.

***Patient involvement***

Patients were not involved in formulating the research question or the outcome measures, nor did they participate in the design and implementation of the study. The findings of this project will be presented at the first meeting of the external committee for RestoRes (Research integrity in biomedical research), funded by the French Agence Nationale de la Recherche under grant agreement ANR-23-CE36-0006. This committee, which includes patient representatives and citizens, will be consulted to discuss the implications of the findings and determine the concrete actions to be implemented following this research project.

***Open access***

Data and code to reproduce the analysis are available on the Open Science Framework (https://osf.io/pa9fq/files/osfstorage). EPARs used for the study are cited via the EMA link.

**Results**

***Selection of EPARs, GCPs, published articles***

Between 17th of July 2000 (date of publication of the first EPAR) up to April 2024 we screened 285 EPARs of refused or withdrawn applications. Fifty-seven (20%) of those were included (13–69) (presented in the supplementary references section) as they mentioned a GCP inspection. Those 57 EPARs referred to 74 different studies, 54 (73%) with a registered identification number (NCT or EudraCT). Among the 74 studies, 58 (in 45/57 EPARs) could be related to at least one publication. Among those, 52/58 studies (90%) were related to only one publication, and 6/58 (10%) to 2. Three publications reported results of 2 studies. This resulted in a total of 61 publications (70–130). One drug, masitinib, was related to 3 different EPARs (39,54,58), all mentioning critical findings in 3 studies, all casting doubts on the data integrity, and leading to 4 publications (70,94,101,102). **Figure 1** describes the selection process.

***Description of the deviations in the EPARs***

26/57 EPARs (46%) did not specify whether the GCP inspection findings were classified as critical, major, or minor. 20/57 (35%) EPARs reported “critical” findings during the GCP

inspections, and 27 (47%) reported "major" findings (presence of critical and major findings are not exclusive within an EPAR, based on EMA definitions). As described in 34/57 (60%) EPARs, the deviation affected the efficacy outcome in 26/34 (76%), the safety in 20/34 (59%) and ethics in 4/34 (12%) (deviations can be observed in multiple aspects of the study within an EPAR). Among the 57 EPARs, the GCPs findings were classified as "impacting the reliability of the data" (in at least on study mentioned in the EPAR) for 28/57 (49%) and "not impacting the reliability of the data" for 19/57 (33%). For 10/57 (18%), details were insufficient to judge the impact on reliability of the data from included studies. **Figure 2** describes the correspondence between EMA's classification and the impact on data reliability. Information on the number of deviations per inspection was missing in 39/57 (68%) EPARs. A median of 0 (IQR: 0-2.75) critical deviations were identified in the remaining reports. In the EPARs mentioning critical deviations (n=20/57; 35%)), the number of critical deviations was described in 6/20 (30%). A median of 5 (IQR 3.25-9.75) critical deviations were reported. Those results are summarized in **Supplementary Table 1**.

***Mention of the deviation and/or of the EMA GCP inspection in the published record***

The information on all publications is available in **Supplementary Table 2**. Regarding our primary outcome, only 1/61 (2%) mentioned GCP inspection findings in the publication (131). This article discussed naproxcinod for knee osteoarthritis. The EPAR excluded data from a site due to GCP breaches, including lack of informed consent and recruitment of site personnel or their associates. It noted in the publication: "1 site excluded due to quality issues, and 1 patient excluded having been randomized at 2 sites." (131). The number of patients in the EPAR and the article matched (28). However, as detailed in **Figure 3**, the corresponding EPARs were released in the public sphere after the publication for 44/61 (72 %) publications. Among those, the GCP inspection occurred after publication for 20 and was unknown for an additional 24. In such cases, we found no corrections, expressions of concern, retractions, related to the GCP inspection findings. One of those studies (102) had a correction related to an undisclosed conflict of interest (132).

For 21 publications (36%), the EPAR indicated that the GCP inspection did not affect the reliability of the data. For 14 publications (20%), the impact on data reliability was not described or was ambiguous. For 26 publications (43%) the EPAR indicated that GCP findings raised concerns about data reliability. The results are summarized in **Figure 3**. Only 2/61 (3%) publications (94,102) had comments on Pubpeer concerning the CGP inspection. They both were related to studies with critical deviations and data reliability issues (54,58). Actualy, both

of thwse comments were posted by a member of our team before the start of our meta-research study.

Among the 16/74 (22%) unpublished studies, the EPAR indicated that the GCP inspection did not affect the reliability of the data in 5/16 (31%). For 5/16 (31%), the impact on data reliability was not described or was ambiguous. For the remaining 6/16 (38%), the EPAR indicated that GCP findings raised concerns about data reliability (**Supplementary Table 3**).

***Deviations, publications and dissemination of studies with data reliability issues***

For the 26 studies with data reliability issues, the verbatim text of the EPAR mentioning the main findings and the journals in which those studies were published are presented in **Table 1**. The only journals with multiple published articles of this category were *The New England Journal of medicine* (n=6, 23%), *The Lancet* (n=2, 8%), *Annals of Oncology* (n=2, 8%). Those studies with reliability issues were published between November 2004 and October 2024 and had a median citation number of 135 (IQR 46;308.5) and a median citation number by meta-analyses of 5 (IQR 1;9.5).

*Detailed inspection reports*

The EMA policy stipulates that "each access to documents request cannot exceed 2 documents". Our first request for access to GCP inspection reports was made the 4th of December 2024 and concerned emapalumab and daprodustat. To date 2nd of May 2025, we had no answers.

**Discussion**

***Statement of principal findings***

Among 285 EPARs concerning drugs that were not authorized in the European Union, we found 57 that mentioned a GCP inspection including at least 28 with issues that were considered as affecting reliability of study results. Of those, 24 studies were published in 26 papers. None of those publications acknowledged the issues or were subsequently corrected after publication. While health authorities' GCP inspection reports serve as a significant source of information, regulators cannot ensure their uptake by the publication ecosystem. This is particularly regrettable given that the medical journals publishing these articles — including the New England Journal of Medicine, The Lancet, and JAMA — are among the most prestigious and are widely regarded as trusted sources of evidence by clinicians, researchers, and public health decision-makers. Many of their readers may be unfamiliar with the highly technical and detailed EPARs and instead rely on journal articles that could fail to provide the full picture for a given drug trial. Journals stand to gain significantly from such independent GCP inspections, which offer a level of scrutiny and depth that far exceeds what peer review alone can deliver. This additional layer of oversight could strengthen the credibility and reliability of the content they

publish. We do not believe that all studies with potential reliability issues should be retracted. In some cases, the concerns may affect only a subset of outcomes or analyses (for example for daprodustat (68,118), where exclusion of sites did not change the overall results). Nonetheless, journals have a responsibility to clearly indicate which parts of a study appear robust and which are questionable or irreparably flawed. The list provided in this paper may be an invaluable resource for achieving this objective.

***Strengths and weaknesses of the study***

Our study addresses a novel and underexplored topic of high importance when considering the quality of the medical literature and its ability to self-correct. While we adopted a comprehensive approach by examining all rejected or withdrawn EPARs, several limitations should be acknowledged. Despite the EMA's efforts to promote transparency, EPARs often lack sufficient detail about GCP inspections, leaving the nature and impact of identified issues unclear in many cases.

Due to our conservative data analysis, which only included explicit concerns and excluded "unclear" situations, we may have overlooked some problematic studies. Studies lacking data reliability assessment and GCP findings description should indeed be approached with caution. For example, for vitespen (23,129), the EPAR states that "the inspection concluded that the pivotal phase 3, randomized, open-label, international clinical trial (C-100-12) was conducted in accordance with Good Clinical Practices. During these inspections, no critical findings were observed but 17 major findings were reported, 3 of which impacted on the results." As there was no mention of data reliability issues, the exact impact on the findings was not precisely described, and the EMA used the data for analysis, we included this study in the "unknown" reliability category. Another example could be biotin for the treatment of progressive multiple sclerosis for multiple sclerosis (56,125), where this seemingly contradictory sentence can be found: "while there are a number of findings that may have impacted the rights of the patients, the quality and integrity of the data and potentially the results of the trial, the source data appeared to be reliable." As there was a mention that source data are reliable the exact impact on the findings was not precisely described, and the EMA used the data for analysis, we included this study in the "not impacting the reliability of the data" category. In these situations, a review of complete GPC inspection records could be beneficial. However, our requests for these reports have proven largely ineffective due to administrative constraints, with delays so long as to render the process practically unusable.

To facilitate the identification of EPARs that may contain GCP-related issues, we focused our analysis on refused and withdrawn EPARs. This choice has important implications

for both internal and external validity. Regarding internal validity, this approach may introduce selection bias and overestimate the frequency or severity of problems. It is reasonable to assume that studies supporting approved drugs are generally more robust, as these drugs are expected to be backed by more trustworthy evidence and less likely to have critical GCP findings impacting the data, even if this remains to be proven.

In terms of external validity, the clinical relevance of our findings may be limited, as these drugs are not approved for use in the European market. However, this limitation is mitigated by the facts that some of these products may be used off-label, some are marketed in other regions (e.g., ceftobiprole (26), in the USA and Canada), all potentially serve as the basis for further research concerning broader pharmacological class (e.g., Naproxinod (28), or treprostinil sodium (24)) and some may be ultimately marketed in European Union (EU) following a new market application (e.g., abaloparatide (57)). Furthermore, our focus was on the reliability of the published studies' records, which is relevant regardless of drug approval status. It is also important to note that our focus was on drugs undergoing market authorisation submission, thus our analysis concerned mostly large pivotal trials sponsored by pharmaceutical companies. Consequently, our findings may not be applicable to other studies, including those conducted in academic settings, which may also be subject to various audit procedures.

***Strengths and weaknesses in relation to other studies, discussing important differences in results***

Bearing these limitations in mind, our study aligns with and replicates findings from the previous analysis of FDA data by Seife (6) with several subtle differences. Both studies found that violations of GCP identified by health authorities are almost never reported in peer-reviewed literature. In addition, these analyses offer complementary insights; Seife's analysis provides detailed observations, but sometimes lacks clarity on the exact impact of GPC violations on study results (6). As illustrated in our study, health authorities might have identified "critical findings" (EMA) or "official action indicated" (the most severe classification by the FDA (6)) that do not affect the data reliability or that are not clinically relevant. Without direct access to GPC inspections, our analysis is less precise, but CHMP's assessment of impact on study results helps identify studies critically needing mention of inspections in their publication. Despite challenges in following a few CHMP opinions (e.g., biotin (56) and vitespen (23)), where the EMA's verbatim text seems to contradict its own conclusions), both GCP reports and expert committee analyses are valuable for end users. Importantly, only one study (28,131) was included in both Seife's and our analyses, with different yet compatible conclusions. In Seife's study, the findings of the inspection report were classified as falsification

and protocol violations, but no definitive link could be made with the reliability of the published study (6). In our study, the EPAR clearly describe the relation of the findings with the involved study on naproxinod for knee osteoarthritis (131). However, while protocol violations regarding inclusion criteria were acknowledged, falsification was not mentioned in the EPAR.

Our findings are also consistent with a substantial body of literature on reporting bias, which suggests that data from health authorities provide a much more accurate picture than published data—most notably illustrated by the seminal study on publication bias in antidepressant trials where most trials with "negative" results in FDA records were either unpublished or published with "positive" results in the journal literature (133).

***Meaning of the study: possible explanations and implications for clinicians and policymakers***

All these results show a clear gap between health authorities' data and medical literature. First, journal processes appear suboptimal, particularly for correcting the record. There is considerable data on the limitations of post-publication peer review as currently implemented (134–137). While most medical journal editors follow the Committee for Publication Ethics recommendations (138), which advocate for and facilitate post-publication comments and offer guidance on addressing criticisms of articles, such comments are often not sufficiently encouraged by journals. Journals often enforce editorial policies that set word or time constraints following the initial publication of an article (139). Journals occasionally offer online comments but those often lack visibility. We did not systematically search for such comments, as they are beyond the scope of our study but we found two studies (about anamorelin (124) and inactivated influenza virus vaccine for children (128)) that were subject of online comments about the GCP inspection (140,141). These comments explicitly pointed out the issues with data reliability. However, no correction was made to the studies despite those comments. Consequently, post-publication peer review is underdeveloped and often ineffective. For example, insufficient actions were taken when instances of outcome switching were identified and reported to the editors of leading medical journals (135). This highlights the need for change. In our specific context, the added value of GCP inspection reports warrants the implementation of several targeted actions. When the inspection precedes publication of the clinical trial, reporting guidelines such as CONSORT (142) could be more explicit about strongly recommending the report of such inspections. Accordingly, journal policies must require reporting of any GCP findings that questions data reliability. If the inspection occurs after publication, journals should require authors to correct the record in case of any GCP inspection raising concerns about data reliability of their study. COPE could clarify that failing to report and address GCP outcomes questioning study reliability constitutes scientific

misconduct as it violates ethical standards. However, it remains to be determined who should be responsible for communicating GCP inspections findings to medical journals. Open science models connecting the various institutions involved in clinical trial governance - including health authorities - with the publication records have been proposed (143,144).

Authors of research papers have a responsibility to report critical CGP irregularities to the editors in a clear and timely manner. However, the case of the RECORD-4 trial (145) published in 2009, has revealed limitations in this approach even in the rare case where a correction was made. Several significant issues were identified by the FDA in 2014 and they were also brought to light by Seife's investigation in 2015 (6). However, the RECORD-4 publication was not corrected until 2022, when the first author acknowledged that "in October 2022, concerns about the accuracy of data presented in the article were brought to [his] attention" and that the FDA report had been "previously unknown to the RECORD4 Steering Committee" (146).

An alternative approach would be to rely on sponsors to declare information about GCP inspections to journals. Initiatives like Good Pharma scorecard (147) may help in this regard by providing adequate incentives. This project aims to monitor desirable aspects of clinical research among pharmaceutical companies to enhance their practices. Transparency about GCPs inspections may reinforce trust in the company, not only for its ability to correct the record when needed, but also, in a more positive way, when those reports show no concerns. However, relying on sponsors may be seen as wishful thinking, considering the inherent conflicts of interest at play (148).

Therefore, in the absence of concrete mechanisms for accounting for GCP inspections outcomes in the medical literature, we believe that studies like this one and initiatives like PubPeer (a site dedicated to post publication peer review) (11) are essential to raise awareness until systemic action is implemented. Unfortunately, Pubpeer appeared in our study to be underused. To support such initiatives the least health authorities such as EMA can do is to publicly release their inspection findings. However, there is currently no publicly available list at EMA.

***Unanswered questions and future research***

This systematic analysis of GCP inspections, as documented in the EPARs of drugs not authorized in the European Union, identified several studies published in the medical literature that warrant correction. These studies likely convey inaccurate messages, even potentially exposing patients to off-label use of drugs without a clear understanding of their harm–benefit ratio or steering the research community toward misguided directions. Future research projects

that should analyse full GCP inspection reports—when available—and extend this line of inquiry to drugs approved by the EMA. Further research should also focus on developing effective strategies for correcting the scientific record.

**What is already known on this topic**

In evidence-based medicine, reliable decision making relies on the best available evidence, usually from the medical literature

However, the pre-publication peer review system is known to have several weaknesses, particularly not being able to conduct inspection on trial sites.

Good clinical practice inspections performed by the Food and Drug Administration are unfrequently reported in the medical literature.

**What this study adds**

This study showed that using the data from the European Medicine Agency is a valuable way to identify published studies, that may need corrections.

The data from the European Medicine Agency are complementary to those from the Food and Drug Administration.

The post-publication peer review system still needs improvements, to offer the best evidences for decision making.

**Ethics statements**

Ethical approval

Not required.

**References:**

To increase readability, references 13 to 69 (corresponding to EPARs) are provides in supplementary material.


1. Smith R. Peer review: a flawed process at the heart of science and journals. J R Soc Med. 2006;99:178-82.

2. Tennant JP, Ross-Hellauer T. The limitations to our understanding of peer review. Res Integr Peer Rev. 2020;5:6.

3. Carlisle JB. False individual patient data and zombie randomised controlled trials submitted to Anaesthesia. Anaesthesia. 2021;76:472-9.

4. Carlisle JB. The analysis of 168 randomised controlled trials to test data integrity. Anaesthesia. 2012;67:521-37.

5. Doshi P. No correction, no retraction, no apology, no comment: paroxetine trial reanalysis raises questions about institutional responsibility. BMJ. 2015;351:h4629.

6. Seife C. Research Misconduct Identified by the US Food and Drug Administration: Out of Sight, Out of Mind, Out of the Peer-Reviewed Literature. JAMA Intern Med. 2015;175:567-77.

7. What we publish on medicines and when | European Medicines Agency. available on: https://www.ema.europa.eu/en/medicines/what-we-publish-medicines-when

8. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

9. Committee for Medicinal Products for Human Use (CHMP) | European Medicines Agency]. Available on: https://www.ema.europa.eu/en/committees/committee-medicinal-products-human-use-chmp

10. Good clinical practice (GCP) inspection procedures | European Medicines Agency (EMA). Available on: https://www.ema.europa.eu/en/human-regulatory-overview/research-development/compliance-research-development/good-clinical-practice/good-clinical-practice-gcp-inspection-procedures

11. PubPeer - Search publications and join the conversation. Available on: https://pubpeer.com/static/about

12. European Medicines Agency policy on access to documents POLICY/0043. Available on: https://www.ema.europa.eu/documents/other/policy/0043-european-medicines-agency-policy-access-documents_en.pdf

70. Adenis A, Blay JY, Bui-Nguyen B, et al. Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial. Ann Oncol. 2014;25:1762-9.

71. Baerwald C, Verdecchia P, Duquesroix B, Frayssinet H, Ferreira T. Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: a randomized, double-blind, parallel-group, multicenter study. Arthritis Rheum. 2010;62:3635-44.

72. Baruchel A, Bertrand Y, Thomas X, et al. Updated Clinical Activity of Graspa Versus Native l-Asparaginase in Combination with Cooprall Regimen in Phase 3 Randomized Trial in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517). Blood. 2015;126:3723.

73. Burillon C, Huot L, Justin V, et al. Cultured autologous oral mucosal epithelial cell sheet (CAOMECS) transplantation for the treatment of corneal limbal epithelial stem cell deficiency. Invest Ophthalmol Vis Sci. 2012;53:1325-31.

74. Chetter I, Stansby G, Sarralde JA, et al. A Prospective, Randomized, Multicenter Clinical Trial on the Safety and Efficacy of a Ready-to-Use Fibrin Sealant as an Adjunct to Hemostasis during Vascular Surgery. Ann Vasc Surg. 2017;45:127-37.

75. Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631-6.

76. Davis MD, Sheetz MJ, Aiello LP, et al. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema. Invest Ophthalmol Vis Sci. 2009;50:1-4.

77. de Botton S, Brandwein JM, Wei AH, et al. Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis. Cancer Med. 2021;10:6336-43.

78. Dember LM, Hawkins PN, Hazenberg BPC, et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med. 2007;356:2349-60.

79. Demetri GD, Chawla SP, Ray-Coquard I, et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to

control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol. 2013;31:2485-92.

80. Fishbane S, Schiller B, Locatelli F, et al. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med. 2013;368:307-19.

81. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495-507.

82. Hauser RA, Shulman LM, Trugman JM, et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord. 2008;23:2177-85.

83. Hickish T, Andre T, Wyrwicz L, et al. MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2017;18:192-201.

84. Hii J, Pivot X, Mclendon K, et al. Establishing analytical and clinical similarity between HD201 and herceptin. J Clin Oncol. 2020;38(15_suppl):579-579.

85. Immonen A, Vapalahti M, Tyynelä K, et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther. 2004;10:967-72.

86. Janssen RS, Mangoo-Karim R, Pergola PE, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease. Vaccine. 2013;31:5306-13.

87. Kahan Z, Grecea D, Smakal M, et al. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy. BMC Cancer. 2019;19:122.

88. Klopstock T, Tricta F, Neumayr L, et al. Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study. Lancet Neurol. 2019;18:631-42.

89. Ledermann JA, Embleton AC, Raja F, et al. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;387:1066-74.

90. Leonardi A, Pisella PJ, Benítez-Del-Castillo JM, et al. NOVATIVE: A Phase II/III, Multicenter, Double-masked, Randomized Study of Cyclosporine A 0.05% and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients with Vernal Keratoconjunctivitis. Clin Ther. 2023;45:1284-8.

91. LeWitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces « off » time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008;63:295-302.

92. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456-65.

93. Locatelli F, Jordan MB, Allen C, et al. Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. N Engl J Med. 2020;382:1811-22.

94. Lortholary O, Chandesris MO, Bulai Livideanu C, et al. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet. 2017;389:612-20.

95. Manich CS, O'Shaughnessy J, Aftimos PG, et al. LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician's choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer. Ann Oncol. 2021;32:S1288.

96. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55:1915-22.

97. Meyburg J, Opladen T, Spiekerkötter U, et al. Human heterologous liver cells transiently improve hyperammonemia and ureagenesis in individuals with severe urea cycle disorders. J Inherit Metab Dis. 2018;41:81-90.

98. Miller PD, Hattersley G, Riis BJ, et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. JAMA. 2016;316:722-33.

99. Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M, Japanese Istradefylline Study Group. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Mov Disord. 2010;25:1437-43.

100. Mizuno Y, Kondo T, Japanese Istradefylline Study Group. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. Mov Disord. 2013;28:1138-41.

101. Mora JS, Bradley WG, Chaverri D, et al. Long-term survival analysis of masitinib in amyotrophic lateral sclerosis. Ther Adv Neurol Disord. 2021;14:17562864211030365.

102. Mora JS, Genge A, Chio A, et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Front Degener. 2020;21:5-14.

103. Nathan RA, Nolte H, Pearlman DS, P04334 Study Investigators. Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids. Allergy Asthma Proc. 2010;31:269-79.

104. Naumann RW, Coleman RL, Burger RA, et al. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2013;31:4400-6.

105. Nguyen QD, Merrill PT, Clark WL, et al. Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA). Ophthalmology. 2016;123:2413-23.

106. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis. 2008;46:647-55.

107. O'Riordan W, Green S, Overcash JS, et al. Omadacycline for Acute Bacterial Skin and Skin-Structure Infections. N Engl J Med. 2019;380:528-38.

108. Pachl J, Svoboda P, Jacobs F, et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis. 2006;42:1404-13.

109. Pavesio C, Zierhut M, Bairi K, Comstock TL, Usner DW, Fluocinolone Acetonide Study Group. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology. 2010;117:567-75, 575.e1.

110. Pourcher E, Fernandez HH, Stacy M, Mori A, Ballerini R, Chaikin P. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism Relat Disord. 2012;18:178-84.

111. Ravandi F, Ritchie EK, Sayar H, et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015;16:1025-36.

112. Rosenbaum JT, Committee R the LS. LUVENIQTM (LX211/Voclosporin) as Corticosteroid-Sparing Therapy in Sight-Threatening Non-Infectious Uveitis: Results From Three Prospective, Randomized, Multicenter, Double-Masked, Placebo-Controlled Phase 2/3 Clinical Trials. Invest Ophthalmol Vis Sci. 2009;50(13):2021.

113. Roy DC, Walker I, Maertens J, et al. ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia. Leukemia. 2020;34:1907-23.

114. Roy DC, Walker I, Maertens J, Lewalle P, et al. Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies. Blood. 2018;132(Supplement 1):120.

115. Schnitzer TJ, Kivitz A, Frayssinet H, Duquesroix B. Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter study. Osteoarthritis Cartilage. 2010;18:629-39.

116. Schnitzer TJ, Hochberg MC, Marrero CE, Duquesroix B, Frayssinet H, Beekman M. Efficacy and safety of naproxcinod in patients with osteoarthritis of the knee: a 53-week prospective randomized multicenter study. Semin Arthritis Rheum. 2011;40:285-97.

117. Singh AK, Carroll K, McMurray JJV, et al. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med. 2021;385:2313-24.

118. Singh AK, Carroll K, Perkovic V, et al. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021;385:2325-35.

119. Stacy M, Silver D, Mendis T, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology. 2008;70:2233-40.

120. Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130:722-31.

121. Stets R, Popescu M, Gonong JR, et al. Omadacycline for Community-Acquired Bacterial Pneumonia. N Engl J Med. 2019;380:517-27.

122. Strand V, Kremer J, Wallenstein G, et al. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. Arthritis Res Ther. 2015;17:307.

123. Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381:29-39.

124. Temel JS, Abernethy AP, Currow DC, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17:519-31.

125. Tourbah A, Lebrun-Frenay C, Edan G, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Mult Scler. 2016;22:1719-31.

126. Turner N, Saura C, Aftimos P, et al. Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP). J Clin Oncol. 2025;43:513-23.

127. van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559-70.

128. Vesikari T, Knuf M, Wutzler P, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med. 2011;365:1406-16.

129. Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008;372:145-54.

130. Xavier P, Hii CSJ, Mclendon K, et al. 166MO A phase III trial to compare the efficacy, safety, pharmacokinetics and immunogenicity of HD201 to trastuzumab in HER2+ early breast cancer patients (TROIKA). Ann Oncol. 2020;31:S307.

131. Schnitzer TJ, Hochberg MC, Marrero CE, Duquesroix B, Frayssinet H, Beekman M. Efficacy and safety of naproxcinod in patients with osteoarthritis of the knee: a 53-week prospective randomized multicenter study. Semin Arthritis Rheum. 2011;40:285-97.

132. Correction. Amyotroph Lateral Scler Front Degener. 2024;25:223.

133. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358:252-60.

134. Besançon L, Bik E, Heathers J, Meyerowitz-Katz G. Correction of scientific literature: Too little, too late! PLoS Biol. 2022;20:e3001572.

135. Goldacre B, Drysdale H, Dale A, et al. COMPare: a prospective cohort study correcting and monitoring 58 misreported trials in real time. Trials. 2019;20:118.

136. Ioannidis JPA. Why Science Is Not Necessarily Self-Correcting. Perspect Psychol Sci. 2012;7:645-54.

137. Shivantha S, Au NLS, Gurrin L, Thornton J, Nielsen J, Mol BW. Publishers' Response to Post-Publication Concerns About Clinical Research in Women's Health. BJOG Int J Obstet Gynaecol. 2025;132:892-901.

138. COPE: Committee on Publication Ethics. COPE: Committee on Publication Ethics. Available on: https://publicationethics.org/

139. Hardwicke TE, Thibault RT, Kosie JE, et al. Post-publication critique at top-ranked journals across scientific disciplines: a cross-sectional assessment of policies and practice. R Soc Open Sci. 2022;9:220139.

140. Schuler US. On the ROMANA 1 and 2 studies on anamorelin. Lancet Oncol. 2022;23:e236.

141. Sancho A, Melchiorri D, Abadie E, Committee for Medicinal Products for Human Use, European Medicines Agency. More on influenza vaccine in young children. N Engl J Med. 2012;366:2528.

142. Hopewell S, Chan AW, Collins GS, et al. CONSORT 2025 Statement: Updated Guideline for Reporting Randomized Trials. JAMA. 2025; Epub ahead of print

143. Siebert M, Naudet F, Ioannidis JPA. Peer review before trial conduct could increase research value and reduce waste. J Clin Epidemiol. 2023;160:141-6.

144. Naudet F, Siebert M, Boussageon R, Cristea IA, Turner EH. An open science pathway for drug marketing authorization—Registered drug approval. PLOS Med. 2021;18:e1003726.

145. Turpie AGG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373:1673-80.

146. Turpie AGG. Revisiting RECORD4. Lancet. 2022;400:2047-8.

147. Miller J, Ross JS, Wilenzick M, Mello MM. Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices. BMJ. 2019;366:l4217.

148. Smith R. Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies. PLoS Med. 2005;2:e138.

**Figure Legend:**

**Figure 1**: Flow chart of the study.

**Figure 2**: Sankey diagram showing the classification of Good Clinical Practice inspection in relation to reliability assessment by the Committee for Medicinal Products for Human Use. The data and code necessary to replicate the figure can be accessed through the Open Science Framework (https://osf.io/pa9fq/).

**Figure 3:** Chart showing the date of the inspection report (blue points), the date of the publication of the European public assessment report (orange points), and the date of the publication in a medical journal (black points), along with EMA's evaluation regarding the reliability of the findings, mention in the publication, and subsequent correction, retraction, or expression of concern.

- = data reliability non affected;

+ = data reliability affected;

? = unknown impact of the inspection's findings on data reliability;

' = no mention of the findings expected;

* = Findings that may or may not be relevant to report, as it was unclear whether the reliability was affected.

The data and code necessary to replicate the figure can be accessed through the Open Science Framework (https://osf.io/pa9fq/).

**Table 1**: Studies with inspection findings affecting the data reliability. Selected elements of the description of the good clinical practice inspection are provided.

Legend: MA = meta-analysis; GCP = Good clinical practice; CSR = Clinical study report; CHMP = Committee for Medicinal Products for Human Use; IMP = Investigational medicinal product; AE = Adverse events; SAE = Serious adverse events; AFIRMM = Association Française pour les Initiatives dans la Recherche sur le Mastocyte et la Mastocytose; CRO = Contract research organisation; NAM = National Agency for Medicines; EMEA = European medicine Agencies; MAL= Acute myeloid leukemia; ITT = Intention to treat; PP = per protocol; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index; ILI = influenza like illness; PFS = Progression free survival; BIRC = Blinded independent central review; EMA = European medicine Agencies; CAPA = Corrective and Preventive Action; MAA = marketing authorisation applications; rhEPO = recombinant human erythropoietin; SmPC = Summary of product characteristics; EPAR = European public assessment report; ESMO = European Society for Medical Oncology; ASCO = American Society of Clinical Oncology.

**Table 1**: Studies with inspection findings affecting the data reliability. Selected elements of the description of the good clinical practice inspection are provided.

| ***Drug*** **(International non-proprietary name) and therapeutic indication** | **Journal, year and (reference)** | **GCP inspection description in the public assessment report** | **Citations** | |
|---|---|---|---|---|
| | | | **Total** | **MAs** |
| *Ceftobiprole* in the treatment of complicated skin and soft-tissue infections in adults | Clinical Infectious Diseases, 2008, (106) | "The GCP inspectors recommended the exclusion of the data from 2 out of the 4 investigator sites inspected." "As each round of inspection or audit has led to the exclusion of additional sites, the overall conduct of the trial is questionable and it can no longer be concluded that the conduct of the trial did not undermine its ability to distinguish effective treatments from less effective treatments." "The GCP non-compliance observed in the conduct of the two pivotal clinical trials does not allow the conclusion that the currently available safety database for ceftobiprole is comprehensive and truly reflects all potentially adverse events due to treatment with the compound." | 208 | 12 |
| *Masitinib* in the treatment of malignant gastrointestinal stromal tumour (GIST) | Annals of oncology, 2014, (70) | "The inspection revealed critical deficiencies, which raise concerns about the efficacy and safety data reported in the CSR of the pivotal trial AB07001 for investigator sites 01 and 03 (22 patients' records out of 43 patients in total in the trial representing 51% of the patients in this pivotal trial)". Inspectors cannot recommend that the presented data and CSR is accepted by the CHMP or used for further assessment. | 54 | 6 |
| *Human heterologous liver cells*, in the treatment of urea cycle disorders | Journal of Inherited Metabolic Disease, 2017, (97) | "The inspection revealed critical and major findings related to study design, conduct and oversight of the study, safety reporting, IMP handling, monitoring of the trial and informed consent handling." "The inspection report concluded that the conduct of the trial was GCP non-compliant and recommended the data collected should not be used in the context of the marketing authorisation application." "Furthermore, the results of the GCP inspection raised concern as regards the completeness and reliability of the AE/SAE (serious adverse events) that were reported." | 14 | 0 |
| *Anamorelin*, in the treatment of anorexia, cachexia or unintended weight loss in patients with non-small cell lung cancer | The Lancet Oncology, 2016, (124) | "The inspections revealed several flawed GCP findings, including significant deficiencies in relation to the availability of source data at the investigator sites, availability of the clinical database, collection and reporting of safety data as well as the investigational medicinal product delivery." "The inspection report concluded that safety data reported in the clinical study reports cannot be recommended for assessment". "The GCP inspection conducted in for this application revealed that concomitant medication – other than for tumour treatment – was not systematically collected. A potential impact of e.g. systemic corticosteroids on weight gain could therefore not be assessed." | 415 | 9 |

| ***Drug*** **(International non-proprietary name) and therapeutic indication** | **Journal, year and (reference)** | **GCP inspection description in the public assessment report** | **Citations** | |
|---|---|---|---|---|
| | | | **Total** | **MAs** |
| *Masitinib*, in the treatment of systemic mastocytosis | The Lancet, 2017, (94) | "The following inspection findings were identified during the two clinical site inspections: Missing adverse events from the study report, mistakes in the reporting of abnormal laboratory results as adverse events, failures in the handling of serious adverse events, lack of a database for SAEs." "the GCP inspection has found that the blinding was compromised during the trial" "an incorrect version of the AFIRMM V2 questionnaire was used during the first months of the study, and occasionally thereafter, however the data obtained were pooled with the other data, confusing their interpretation" "The accumulation of critical and major inspection findings, affecting all aspects of the trial, seriously question the reliability of the trial data" | 93 | 2 |
| *Tofacitinib*, in the treatment of rheumatoid arthritis | Arthritis & Rheumatism, 2013, (127) | "However, the major and critical findings suggested some deficiencies in the presentation of data in the CSRs yielding the inspectors to request additional reanalys." "There was concern that the statistical methods employed to handle patients who discontinued from the randomised treatment may overestimate the treatment effect." "Data from patients at Sites 1048 and 1174 were excluded from the FAS." | 455 | 42 |
| *Masitinib,* in the treatment of amyotrophic lateral sclerosis | Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, (102) | "The nature and of the findings, the systematic deficiencies observed, the massive number of protocol deviations which translated into a general lack of adherence to the protocol, the lack of global investigator meetings to harmonise procedures, and the suboptimal quality of management by the sponsor and CROs involved, all have a negative impact on data reliability." "One of the remarked issues in GCP inspection was the fact that similar reasons for withdrawal were registered differently, thus leading to different imputations in the final analysis." "It was concluded that the data obtained at the inspected sites are not trustworthy enough to support the submitted marketing authorisation application for masitinib, and seriously affect the credibility of the data in the whole application." | 135 | 1 |
| *Masitinib,* in the treatment of amyotrophic lateral sclerosis | Therapeutic Advances in Neurological Disorders, 2021, (101) | "The nature and of the findings, the systematic deficiencies observed, the massive number of protocol deviations which translated into a general lack of adherence to the protocol, the lack of global investigator meetings to harmonise procedures, and the suboptimal quality of management by the sponsor and CROs involved, all have a negative impact on data reliability." "One of the remarked issues in GCP inspection was the fact that similar reasons for withdrawal were registered differently, thus leading to different imputations in the final analysis." "It was concluded that the data obtained at the inspected sites are not trustworthy enough to support the submitted marketing authorisation application for masitinib, and seriously affect the credibility of the data in the whole application." | 38 | 0 |

| ***Drug*** **(International non-proprietary name) and therapeutic indication** | **Journal, year and (reference)** | **GCP inspection description in the public assessment report** | **Citations** | |
|---|---|---|---|---|
| | | | **Total** | **MAs** |
| *Abaloparatide*, in the treatment of osteoporosis | JAMA, 2016, (98) | "critical findings were identified relating to patient's inclusion in the clinical trial, the quality system of the sites and the availability of documents requested during the inspection." " Due to the critical findings observed at two sites in Czech Republic, the inspectors concluded that the data from these sites cannot be reliable, and recommended to exclude them when assessing the marketing authorisation application. The exclusion of these two study sites in the single pivotal study resulted in a reduction of the total study population by 16% from 2463 to 2070 participants." "A significant and clinically relevant efficacy of abaloparatide compared to placebo on non-vertebral fractures has not been established [log-rank p=0.3675; HR (95% CI) 0.74 (0.38, 1.43)]" | 571 | 25 |
| *Emapalumab,* in the treatment of primary haemophagocytic lymphohistiocytosis (HLH) in children under 18 years of age | The New England Journal of Medicine, 2020, (93) | "Inspection resulted towards important critical and major findings related to the patient's rights and the data integrity." "deviations regarding to informed consents as for example, no translated informed consent available; the collection of more medical data and storage of patient samples than was foreseen by the protocol or informed consent, the transfer to the sponsor of personal data like race, ethnicity, and sometimes patient's identity." "the Data Monitoring Committee was not independent as a sponsor representative was always present." "The critical findings found at the Sponsor site, impacted the whole clinical trial. In this case it negatively affected the data collection, data handling, the planning of the transition of the phase II to a phase III trial, statistical analyses, etc." "the study NI-0501-04 was not considered GCP compliant and the integrity of the data is impaired." | 319 | 0 |
| *Herpes simplex virus thymidine kinase gene,* in the treatment of patients with operable high-grade glioma | Molecular Therapy, 2004, (85) | "The NAM regulation and the principles of good clinical practice were not followed in all aspects of the study 903." " Although the study 903 was systematically performed, a valid amended protocol or other valid amendment document was missing for several years during the conduct of the study." "Although the clinical data collected in this study could be verified, the concerns with respect to data quality remain. CRFs were created retrospectively. Thus, only information available in the patients' records was collected retrospectively." "However, there is a large amount of information that is either poorly documented or is lacking in many patients" | 298 | 5 |

| ***Drug*** **(International non-proprietary name) and therapeutic indication** | **Journal, year and (reference)** | **GCP inspection description in the public assessment report** | **Citations** | |
|---|---|---|---|---|
| | | | **Total** | **MAs** |
| *Eprodisate disodium*, in the treatment of amyloid A amyloidosis | The New England Journal of Medicine, 2007, (78) | "A Cox analysis was performed which was not described in the statistical analysis plan, with this analysis subsequently presented as the principal evidence of product efficacy." "The sponsor could not ascertain that the blind was properly maintained throughout the trial." "The explanations and the documentation provided by the applicant were insufficient to guarantee complete reassurance that the randomization list was not used for the purpose of an interim analysis." "Despite additional information and due to a deviation related to the blinding process and lack of documentation, the EMEA cannot be certain that the decision to change the primary efficacy endpoint was not datadriven." "The originally primary endpoint, which included assessment of changes in nephrotic syndrome and gastrointestinal symptoms showed no difference between eprodisate and Kiacta (p= 0.79)." "A sensitivity analysis of the primary outcome imputing all. discontinuations to the “worse” category demonstrated the lack of robustness of the primary outcome (p=0.340)" | 162 | 1 |
| *Lenalidomide*, in the treatment of anaemia due to myelodysplastic syndromes | The New England Journal of Medicine, 2006, (92) | "incomplete reporting of transfusion and non-compliance to transfusion rules which could have led to an overestimation of efficacy." "Non-compliance to transfusion rules predefined by the protocol has been observed in roughly 40% of patients. In addition, in these patients who were not completely followed by the investigators, additional transfusions prescribed outside the study might have impacted on efficacy results" "The applicant provided updated data on deaths and AML occurrence which are further detailed and discussed in the safety section [...] substantially higher incidence of Grade 3 and 4 thrombocytopenia and neutropenia than initially reported." "Major findings were highlighted during the GCP inspection of one investigational site and these observations could affect the reliability of the collected safety data, in particular the rate of AML transformation." | 1009 | 6 |
| *Treprostinil sodium,* in the treatment for patients with pulmonary arterial hypertension | Journal of the American College of Cardiology, 2010, (96) | "Based on the Agency inspections at two different trial sites, the pivotal TRIUMPH study is considered non-GCP compliant and therefore not in accordance with requirements of Directive 2001/83/EC." "The conclusion of non-compliance was based on several critical and major findings in the two investigators sites inspected, pertaining to trial management, and quality of the data." "These issues are considered to have a major impact on the reporting of both efficacy and safety data, Thus, the credibility of the data is questioned and the benefit/risk cannot be assessed based on the currently submitted data" | 422 | 30 |
| *Mometasone furoate and formoterol fumarate*, in the treatment of asthma | Allergy and Asthma Proceedings, 2010, (103) | "a large number of critical and major findings were detected at the 2 other inspection sites." "Due to the deficient monitoring and lack of adequate oversight the data reliability is questionable" | 26 | 5 |

| ***Drug*** **(International non-proprietary name) and therapeutic indication** | **Journal, year and (reference)** | **GCP inspection description in the public assessment report** | **Citations** | |
|---|---|---|---|---|
| | | | **Total** | **MAs** |
| *Naproxcinod* , in the relief of signs and symptoms of osteoarthritis of the knee and hip | Osteoarthritis and Cartilage, 2010, (115) | "A routine GCP inspection for studies HCT 3012-X-301 and HCT 3012-X-303 in two investigator sites and one sponsor site (INS/GCP/2010/04) revealed a critical deviation in the site 804 of study 303: Several discrepancies between Data Listings and source documents (Case report form CRF) regarding the Womac scale values were detected." "Due to the exclusion of data from patients at Site 061/069 (see Section 2.5.4.1.1), (failure to comply with GCP) the efficacy analyses of Studies HCT 3012-X-301 and HCT 3012-X-302 were repeated after sign-off of the reports. The re-analysis of the primary and key secondary efficacy data excluded the data on 36 patients from the ITT and PP populations. when data from Site 061/069 were excluded from Study HCT 3012-X-301 was that the naproxcinod 375 mg bid dose was no longer non-inferior to naproxen 500 mg bid at Week 13 for the WOMACTM pain subscale score." | 38 | 5 |
| *Inactivated influenza virus vaccine,* in the prevention of seasonal influenza in infants and children | The New England Journal of Medicine, 2011, (128) | "Results of the inspection revealed three critical findings and several major findings." "the Inspection performed has put in evidence many relevant failures and the final report recommended not to accept the trial results due to the lack of compliance with GCP." "Moreover, critical findings, questioning the validity of the PCR analysis, were discovered in the central laboratory that analysed all nasal swab samples collected in all study centres." "The GCP Inspection found not only a lack of GCP compliance in the inspected sites but also identified a number of issues, regarding the clinical efficacy data from the pivotal trial, that were inaccurately stated in the first dossier submitted by the Applicant. This greatly impacts the reliability of overall study results." "Moreover, from the efficacy point of view, the finding that none of the 152 children vaccinated at the site was reported to have ILI during the study period (several months) also questions the validity of overall efficacy data obtained in the trial. It is in fact noted that in total 4702 children were recruited in the pivotal trial, and 1114 of them had ILI (i.e., a 23.6% of all vaccinated children) during the trial period. Thus, the probability of not having any child with ILI out of the 152 vaccinated children in the site was: 0.000000000000000002 (= 2x10-18). The fact that the Applicant did include in the efficacy analyses data from this site, which are extremely unlikely to have occurred in reality, suggests that there was no appropriate supervision of the efficacy data by the Applicant." | 244 | 10 |
| *Peginesatide*, in the treatment of symptomatic anaemia associated with chronic kidney disease in adult patients undergoing dialysis | The New England Journal of Medicine, 2013, (80) | "Findings of the GCP inspection identified issues with regards to insufficient oversight and monitoring, irregularities in data handling, out of protocol dosing (adjustment) for the Epoetin groups and concerns with regards to the definition of the PP Population." "However, GCP findings and uncertainties with regards to the PP Population are of major concern and question the overall data validity." "This is of particular importance in non-inferiority." "Efficacy in the maintenance treatment is not considered confirmed in the presence of GCP findings and uncertainties with regards to reliability of the data trials, where a clean study conduct is required to minimize the risk that true differences between treatments would not become apparent." | 71 | 2 |

| ***Drug*** **(International non-proprietary name) and therapeutic indication** | **Journal, year and (reference)** | **GCP inspection description in the public assessment report** | **Citations** | |
|---|---|---|---|---|
| | | | **Total** | **MAs** |
| *Vaccine which contains hepatitis B surface antigen* , in the prevention of hepatitis B infection | Vaccine, 2013, (86) | "Due to the lack of quality system by the sponsor, the insufficient instruction with regard to IMP handling, storage and keeping the study blind as well as the incorrectness of the clinical study report in a number of fields, the data of trial DV2-HBV-17 are considered non-acceptable and the inspectors recommend not to use the data of trial DV2-HBV-17 in the context of the evaluation of the marketing authorisation application of Heplisav." "The pivotal study, HBV-17 is not considered to contain sufficiently reliable data due to GCP issues." "The findings related to the inappropriate quality assurance and quality control system are considered to be process-related and therefore apply for the entire study. Most likely, those findings also impact previous and on-going studies performed by the sponsor." | 56 | 1 |
| *Human fibrinogen and human thrombin*, in the treatment of bleeding during vascular surgery | Annals of Vascular Surgery, 2017, (74) | "The findings observed at the three sites inspected have a relevant impact on the quality and integrity of the data." "Several GCP breaches where identified at all sites inspected including the sponsor and the affiliate and all of them along with the CRO critical performance contributed to the fact that data are not considered trustworthy." "Some data included in the CSR could not be verified during the source data verification process as they were not in any of the source documents used at sites." "This has an impact on data consistency and of course and on data integrity." "At the sites discrepancies on surgical and non-surgical events were observed and a deficient management of safety documentation." | 17 | 4 |
| *Cediranib*, in the treatment of ovarian cancer | The Lancet, 2016, (89) | "A total of four study sites were inspected (of 62 participating study centers). The inspections revealed several GCP findings. The main issues were related to:<br>- Oversight by the study sponsor which resulted in non-uniform conduct and reporting of data.<br>- The impact of post-unblinding activities on the reported data<br>- Lack of available documentation of the appearance of test and control product meant the blinding process is not verifiable.<br>- The safety profile was considered incomplete, A routine inspection revealed issues, the impact of which can still not be fully assessed.”<br>“The most important remaining issues pertain to the reliability of the data and the integrity of the database. Based on an initial concordance analysis, there were important differences between investigator assessed PFS and PFS by BICR for 15 out of 36 evaluable patients in three inspected sites (i.e. 41% discordance), questioning the reliability of the adjudication of PFS" | 193 | 15 |

| ***Drug*** **(International non-proprietary name) and therapeutic indication** | **Journal, year and (reference)** | **GCP inspection description in the public assessment report** | **Citations** | |
|---|---|---|---|---|
| | | | **Total** | **MAs** |
| *Trastuzumab*, in the treatment of certain forms of breast cancer and gastric (stomach) cancer. | Annals of oncology (ESMO abstract), 2020, (130) | "The GCP inspection for the phase III TROIKA study (EudraCTnr: 2016-004019-11; EMA Inspection reference number: GCP/2019/022) revealed critical GCP non-compliance that affected the credibility of the data." "Further to several critical findings during GCP-inspections and re-inspections, the applicant presented an updated clinical study report." "In addition, as a result of the CAPA arising from the requested GCP inspection of the TROIKA study, neo-adjuvant subject data was 100% re-monitored and resubmitted, because substantial amounts of previously unreported safety data was discovered." "Even if the discrepancies and lack of updating of reports had been partly sorted out, uncertainties remained regarding biosimilarity, due to concern regarding critical findings from the GCP inspections and re-inspections of the TROIKA study." | NA | NA |
| *Trastuzumab*, in the treatment of certain forms of breast cancer and gastric (stomach) cancer. | Journal of clinical oncology (ASCO abstract), 2020, (84) | "The GCP inspection for the phase III TROIKA study (EudraCTnr: 2016-004019-11; EMA Inspection reference number: GCP/2019/022) revealed critical GCP non-compliance that affected the credibility of the data." "Further to several critical findings during GCP-inspections and re-inspections, the applicant presented an updated clinical study report." "In addition, as a result of the CAPA arising from the requested GCP inspection of the TROIKA study, neo-adjuvant subject data was 100% re-monitored and resubmitted, because substantial amounts of previously unreported safety data was discovered." "Even if the discrepancies and lack of updating of reports had been partly sorted out, uncertainties remained regarding biosimilarity, due to concern regarding critical findings from the GCP inspections and re-inspections of the TROIKA study." | NA | NA |
| *Trastuzumab-duocarmazine* in the treatment of HER2-positive breast cancer | Annals of Oncology (ESMO abstract), 2021, (95) | "the inspection at the Singapore site was impaired by multiples administrative difficulties, and led to several critical findings, especially with regards to direct access to the electronic medical records of subjects." "Due to important difficulties to access and control the study records, inspectors were of the opinion that these data could not be used in the context of a MAA." "Moreover, when inspecting the Sponsor's site, it was found that 11 other sites did not give full access to their electronic source data to the sponsor, but relied on paper documentation. These 12 investigational centres represented 17% of the study population, for which a very strong degree of uncertainty on the reliability of the data is identified." "The GCP inspection identified critical findings on the sponsor's lack of access to source data from 12 of the 78 clinical sites, representing 75 patients out of 473, leading to GCP uncompliant monitoring of these sites and potentially impairing data integrity". | NA | NA |

| ***Drug*** **(International non-proprietary name) and therapeutic indication** | **Journal, year and (reference)** | **GCP inspection description in the public assessment report** | **Citations** | |
|---|---|---|---|---|
| | | | **Total** | **MAs** |
| *Trastuzumab-duocarmazine* in the treatment HER2-positive breast cancer | Journal of clinical oncology, 2024, (126) | "the inspection at the Singapore site was impaired by multiples administrative difficulties, and led to several critical findings, especially with regards to direct access to the electronic medical records of subjects." "Due to important difficulties to access and control the study records, inspectors were of the opinion that these data could not be used in the context of a MAA." "Moreover, when inspecting the Sponsor's site, it was found that 11 other sites did not give full access to their electronic source data to the sponsor, but relied on paper documentation. These 12 investigational centres represented 17% of the study population, for which a very strong degree of uncertainty on the reliability of the data is identified." "The GCP inspection identified critical findings on the sponsor's lack of access to source data from 12 of the 78 clinical sites, representing 75 patients out of 473, leading to GCP uncompliant monitoring of these sites and potentially impairing data integrity". | 3 | 1 |
| *Daprodustat*, in the treatment of adult patients with symptoms of anaemia caused by chronic kidney disease | The New England Journal of Medicine, 2021, (118) | "In the study 200808/ASCEND-ND and 200807/ASCEND-D, three and eight sites were closed early due to GCP non-compliance issues, including suspected fraud at one and three sites, respectively; participants from these sites are excluded from the results presented." "Data on 17 study participants (1 randomized) and 10 participants, respectively, were excluded from all analyses as valid informed consent was never obtained." "For the ASCEND-D study, 88 subjects were randomised at three sites, 49 to the daprodustat arm and 39 to the rhEPO arm. There were no meaningful differences between the primary and adjusted analyses for the most relevant endpoints and study outcome of the ASCEND-D study. However, the detailed information on the nature of the issues at the three sites confirmed a high suspicion of fraud, including the alleged fabrication of data. The Applicant's actions concerning the findings, i.e., closure of three sites, is considered acceptable. However, it is considered most correct to present the results with data from the closed sites excluded in the EPAR and SmPC. All tables and figures in the SmPC and/or EPAR containing data from the ASCEND-D study have been substituted with tables and figures with data from the 88 subjects affected by the site closure excluded." | 120 | 17 |

**Legend:** MA = meta-analysis; GCP = Good clinical practice; CSR = Clinical study report; CHMP = Committee for Medicinal Products for Human Use; IMP = Investigational medicinal product; AE = Adverse events; SAE = Serious adverse events; AFIRMM = Association Française pour les Initiatives dans la Recherche sur le Mastocyte et la Mastocytose; CRO = Contract research organisation; NAM = National Agency for Medicines; EMEA = European medicine Agencies; MAL= Acute myeloid leukemia; ITT = Intention to treat; PP = per protocol; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index; ILI =

influenza like illness; PFS = Progression free survival; BIRC = Blinded independent central review; EMA = European medicine Agencies; CAPA = Corrective and Preventive Action; MAA = marketing authorisation applications; rhEPO = recombinant human erythropoietin; SmPC = Summary of product characteristics; EPAR = European public assessment report; ESMO = European Society for Medical Oncology; ASCO = American Society of Clinical Oncology.


EPAR screened
EPAR included
Studies included & publication searched
Publication inlcuded
285 EPAR
228 without GCP inspection mentionned
57 mentionning GCP inspection
74 studies
54 with identification number / 20 without
16 studies without related publications
5 with identification number / 11 without
58 studies related to at least one publication
61 publications


Critical findings
Major findings
No classification of findings
Reliability affected
Reliability not affected
Reliability not stated


Evaluation after publication
45 (74%)
Evaluation before publication
16 (26%)
Istradefylline, Ann Neurol. 2008 ? NO* NO*
Istradefylline, Neurology. 2008 ? NO* NO*
Istradefylline, Mov Disord. 2008 ? NO* NO*
Istradefylline, Mov Disord. 2010 ? NO* NO*
Istradefylline, Parkinsonism Relat Disord. 2012 ? NO* NO*
Istradefylline, Mov Disord. 2013 ? NO* NO*
Trastuzumab, J Clin Oncol. 2020 + NO NO
Herpes simplex virus thymidine kinase gene, Mol Ther. 2004 + NO NO
Voclosporin, Invest Ophthalmol Vis Sci. 2009 ? NO* NO*
Enasidenib, Blood. 2017 - NO' NO'
Trastuzumab, Ann Oncol. 2020 + NO NO
Trastuzumab-duocarmazine, Ann Oncol. 2021 + NO NO
Ceftobiprole, Clin Infect Dis. 2008 + NO NO
Vosaroxin, Lancet Oncol. 2015 - NO' NO'
Daprodustat, N Engl J Med. 2021-1 - NO' NO'
Lenalidomide, N Engl J Med. 2006 + NO NO
Daprodustat, N Engl J Med. 2021-2 + NO NO
Abaloparatide, JAMA. 2016 + NO NO
Vitespen, Lancet. 2008 ? NO* NO*
Deferiprone, Lancet Neurol. 2019 - NO' NO'
Anamorelin, Lancet Oncol. 2016 + NO NO
T-cells from the transplant donor, specially treated to reduce the risk of GVHD, Blood. 2018 - NO' NO'
Serelaxin, Lancet. 2013 - NO' NO'
Biotin, Mult Scler. 2016 - NO' NO'
Autologous oral mucosal epithelial cells, Invest Ophthalmol Vis Sci. 2012 - NO' NO'
Eryaspase, Blood. 2019 - NO' NO'
Naproxcinod, Osteoarthritis Cartilage. 2010 + NO NO
Romidepsin, J Clin Oncol. 2012 ? NO* NO*
Eprodisate disodium, N Engl J Med. 2007 + NO NO
Tofacitinib, N Engl J Med. 2012 - NO' NO'
Omadacycline, N Engl J Med. 2019-2 - NO' NO'
Omadacycline, N Engl J Med. 2019-1 - NO' NO'
Vintafolide, J Clin Oncol. 2013 - NO' NO'
Emapalumab, N Engl J Med. 2020 + NO NO
Efungumab, Clin Infect Dis. 2006 - NO' NO'
Cediranib, Lancet. 2016 + NO NO
Mometasone furoate and formoterol fumarate, Allergy Asthma Proc. 2010 + NO NO
Peginesatide, N Engl J Med. 2013 + NO NO
Inactivated influenza virus strains, N Engl J Med. 2011 + NO NO
Naproxcinod, Arthritis Rheum. 2010 - NO' NO'
Human IgG1 monoclonal antibody specific for human interleukin-1 alpha, Lancet Oncol. 2017 ? NO* NO*
Hepatitis B surface antigen vaccine, Vaccine. 2013 + NO NO
Masitinib, Lancet. 2017 + NO NO
Naproxcinod, Semin Arthritis Rheum. 2011 ? YES* NO*
Tofacitinib, Arthritis Rheum. 2013 + NO NO
Treprostinil sodium, J Am Coll Cardiol. 2010 + NO NO
T-cells from the transplant donor, specially treated to reduce the risk of GVHD, Leukemia. 2020 - NO' NO'
Ridaforolimus, J Clin Oncol. 2013 - NO' NO'
Sirolimus, Ophthalmology. 2016 - NO' NO'
Masitinib, Ann Oncol. 2014 + NO NO
Trastuzumab-duocarmazine, J Clin Oncol. 2024 + NO NO
Masitinib, Amyotroph Lateral Scler Frontotemporal Degener. 2019 + NO NO
Enasidenib, Cancer Med. 2021 - NO' NO'
Ruboxistaurin, Invest Ophthalmol Vis Sci. 2009 ? NO* NO*
Human fibrinogen and human thrombin, Ann Vasc Surg. 2017 + NO NO
Pegfilgrastim, BMC Cancer. 2019 - NO' NO'
Human heterologous liver cells, J Inherit Metab Dis. 2017 + NO NO
Tofacitinib, Arthritis Res Ther. 2015 - NO' NO'
Fluocinolone acetonide, Ophthalmology. 2010 ? NO* NO*
Masitinib, Ther Adv Neurol Disord. 2021 + NO NO
Ciclosporin, Clin Ther. 2023 ? NO* NO*
-15 -10 -5 0 5 10 15
Time (in years) before and after publication
RELIABILITY IS AFFECTED
MENTION IN THE REPORT
SUBSEQUENT CORRECTION